Overview

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib

Status:
Active, not recruiting

Trial end date:
2022-02-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the hypothesis that patients with CML who have not achieved optimal response after 3 months of treatment with imatinib will have a better response by switching to dasatinib compared to staying on their original imatinib regimen.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborators:

Donald E. Morisky
ICON Clinical Research
MD Anderson Symptom Inventory (MDASI-CML)
Molecular MD
MultiPharma
OBiS, Inc
PPD
Q2 Solutions
Steering Committee

Treatments:

Dasatinib
Imatinib Mesylate